Albireo Pharma (FRA:BDQM) Common Stock : €0.21 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Common Stock?

Albireo Pharma's quarterly common stock increased from Mar. 2022 (€0.18 Mil) to Jun. 2022 (€0.19 Mil) and increased from Jun. 2022 (€0.19 Mil) to Sep. 2022 (€0.21 Mil).

Albireo Pharma's annual common stock increased from Dec. 2019 (€0.11 Mil) to Dec. 2020 (€0.16 Mil) and increased from Dec. 2020 (€0.16 Mil) to Dec. 2021 (€0.17 Mil).

Albireo Pharma Common Stock Historical Data

The historical data trend for Albireo Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Common Stock Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Common Stock

Get a 7-Day Free Trial

0.08

0.11

0.16

0.17

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Common Stock	Get a 7-Day Free Trial															0.16	0.17	0.18	0.19	0.21

Albireo Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines